M J Molina-Garrido, A Mora, C Guillén-Ponce, M Guirado-Risueño, M J Molina, M A Molina, A Carrato
{"title":"[Systemic mastocytosis: systematic review].","authors":"M J Molina-Garrido, A Mora, C Guillén-Ponce, M Guirado-Risueño, M J Molina, M A Molina, A Carrato","doi":"10.4321/s0212-71992008000300008","DOIUrl":null,"url":null,"abstract":"<p><p>Mastocytosis is a hematologic malignance characterized by an abnormal proliferation of mastocytes. In a consensus classification in 2001, it was distinguished between matters limited to skin and systemic matters (70% of osseous involvement and 50% of hepatomegaly). The most typical symptoms are skin lesions and systemic manifestations due to mediators secreted by tumoral cells. They are useful chemotherapy to reduce the tumoral burden and antihistaminic to control systemic manifestations. Interferon is useful in most of systemic and local manifestations, and it is recommended to use prednisona before the use of this medication.</p>","PeriodicalId":50798,"journal":{"name":"Anales De Medicina Interna","volume":"25 3","pages":"134-40"},"PeriodicalIF":0.0000,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales De Medicina Interna","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4321/s0212-71992008000300008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 27
Abstract
Mastocytosis is a hematologic malignance characterized by an abnormal proliferation of mastocytes. In a consensus classification in 2001, it was distinguished between matters limited to skin and systemic matters (70% of osseous involvement and 50% of hepatomegaly). The most typical symptoms are skin lesions and systemic manifestations due to mediators secreted by tumoral cells. They are useful chemotherapy to reduce the tumoral burden and antihistaminic to control systemic manifestations. Interferon is useful in most of systemic and local manifestations, and it is recommended to use prednisona before the use of this medication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
